Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients

In This Article:

Existing Klarity-C Patients to Have Access to VEVYE for $59 Per Bottle

NASHVILLE, Tenn., April 10, 2025--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced an expansion of its VEVYE® Access for All ("VAFA") program to include patients currently prescribed Klarity-C Drops®, a compounded cyclosporine 0.1% product manufactured and distributed by ImprimisRx®, Harrow’s compounding subsidiary. Since its launch on March 17, 2025, VEVYE Access for All has simplified dry eye therapy for eligible patients by eliminating access barriers like prior authorization and reimbursement delays, providing free home delivery, and offering a no‑questions-asked, money-back guarantee.1 The VEVYE Access for All program is flexible, allowing patients to choose to use their insurance coverage2 or take advantage of Harrow’s affordable cash price.

As a result of today’s announcement, beginning immediately, more than 25,000 patients across the U.S. will be able to convert their Klarity-C prescriptions to VEVYE (cyclosporine ophthalmic solution) 0.1%, an FDA‑approved treatment for the signs and symptoms of dry eye disease, for $59 per bottle (including refills). As a part of this transition, Klarity-C prescribers have access to a prescription authorization platform to transfer Klarity-C prescriptions to PhilRx in a process that shouldn’t take more than 5 minutes.

"We are pleased to make VEVYE accessible and affordable to Klarity-C patients," said Mark L. Baum, Chief Executive Officer of Harrow. "The secret to the success of VEVYE Access for All is simple: lower costs to patients and eliminate the requirement for prescribers to endure the burden of access obstacles like prior authorizations and step therapy. The result is twofold: dry eye patients receive what their doctor prescribes at an affordable price; and for doctors and their staff, choosing VEVYE is an absolute no‑brainer."

"Pharmaceutical companies have long made promises to tackle the access barriers my colleagues and I encounter when advocating for our patients – especially in the realm of dry eye treatments. Harrow, a company that has consistently brought meaningful innovation to my practice, has delivered once again with VEVYE Access For All," said Alice Epitropoulos, MD, FACS, Partner and Co-founder of the Eye Center of Columbus. "I often prescribed Klarity-C because it provided exceptional value to my patients, particularly those without insurance or with limited coverage. Now, being able to offer VEVYE at that same affordable price point to some of my dry eye disease patients – without the usual insurance hassles – is a game changer. This is true price transparency and accessibility that simplifies care and supports what matters most: better outcomes."

Waiting for permission
Allow microphone access to enable voice search

Try again.